Table 3.
Cox Regression Analysis for Composite Outcomes During the Follow‐up Period in Patients Treated With Tafamidis
| Increase in both hs‐cTnT and BNP (vs decrease in hs‐cTnT, BNP, or both) | HR | 95% CI | P value |
|---|---|---|---|
| Univariable model | 5.06 | 1.84–13.9 | <0.01 |
| Multivariable model 1 (adjusted for age and female sex) | 4.30 | 1.33–13.9 | 0.02 |
| Multivariable model 2 (adjusted for hs‐cTnT and BNP) | 5.11 | 1.54–16.9 | <0.01 |
| Multivariable model 3 (adjusted for LVEF and LV‐GLS) | 6.16 | 1.80–21.0 | <0.01 |
| Multivariable model 4 (adjusted for native T1 and ECV) | 19.7 | 1.83–211 | 0.01 |
| Multivariable model 5 (adjusted for enrichment of HF treatment) | 5.05 | 1.76–14.5 | <0.01 |
Multivariable models were conducted using restricted cubic splines analysis to estimate the nonlinear covariate effects. BNP indicates B‐type natriuretic peptide; ECV, extracellular volume; HF, heart failure; HR, hazard ratio; hs‐cTnT, high‐sensitivity cardiac troponin T; LVEF, left ventricular ejection fraction; and LV‐GLS, left ventricular global longitudinal strain.